#86 1/17/02 Toray

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: GOODWIN et al.

Serial No: 09/628,126

Filed: July 28, 2000

For: CD30 LIGAND

Docket No.: 2804-I

Group Art Unit: 1644

Examiner: M. Jamroz

Assistant Commissioner for Patents
Washington, DC 20231

RESPONSE TO SECOND RESTRICTION REQUIREMENT AND AMENDMENT

On October 31, 2001, a second Restriction Requirement was issued in this application. In response to this second Restriction Requirement, the applicants without traverse hereby elect Group II, directed to claims that cover methods for delivering to cells a conjugate comprising a therapeutic agent and a CD30-ligand polypeptide. Group II includes claim 27-30, 32-39 and 40-46 to the extent that they are directed to the use of therapeutic agent/CD30L conjugates. The claims of Group II have been amended as shown below to delete the non-elected subject matter. The applicants reserve the right to pursue non-elected Group I (claims 27, 28, 32-39 and 40-45, to the extent that they cover the use of diagnostic agent/CD30L conjugates) and Group III (claims 31 and 47-49) at a later time in other patent applications.

Prior to examining the above-referenced application, please enter the following amendments into the application.

In the claims:

27. (TWICE amended) A method of delivering a therapeutic agent to $CD30^+$ cells, comprising contacting said cells with a conjugate comprising one or more therapeutic agents attached to a CD30 ligand (CD30-L) polypeptide.

28. (TWICE amended) A method of delivering a therapeutic agent to $CD30^+$ cells, comprising contacting said cells with a conjugate comprising one or more therapeutic agents attached to a CD30-L polypeptide, wherein said CD30-L polypeptide is a soluble fragment of the human CD30-L of SEQ ID NO:8.